Funding sources This study was supported by Barrier Therapeutics Inc., Princeton, NJ, U.S.A., and Barrier Therapeutics, NV, Geel, Belgium, prior to being acquired by Stiefel, a GSK company, Research Triangle Park, NC, U.S.A.
Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial
Article first published online: 13 JAN 2014
© 2013 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
British Journal of Dermatology
Volume 170, Issue 1, pages 173–181, January 2014
How to Cite
Vahlquist, A., Blockhuys, S., Steijlen, P., van Rossem, K., Didona, B., Blanco, D. and Traupe, H. (2014), Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial. British Journal of Dermatology, 170: 173–181. doi: 10.1111/bjd.12626
Conflicts of interest A.V. has received honoraria for his consultancy roles for Orfagen and GSK. S.B. was an employee of Barrier Therapeutics and owned stock options in the company. P.S. has received honoraria from Abbott for his role as a speaker. K.v.R. was an employee of Barrier Therapeutics and owned stock options in the company; currently an employee of Stiefel (a GSK company) and owns stock and stock options in the company. B.D. is a consultant for Abbott and Wyeth. D.B. has nothing to declare. H.T. has received honoraria for his consultancy role for GSK.
- Issue published online: 13 JAN 2014
- Article first published online: 13 JAN 2014
- Accepted manuscript online: 14 SEP 2013 08:07AM EST
- Manuscript Accepted: 5 SEP 2013
- Barrier Therapeutics Inc.
- Barrier Therapeutics, NV
Table S1. Mean (standard deviation) changes from baseline in Investigator's Global Assessment (IGA) score and symptom scores at weeks 8 and 12, showing statistical significance for comparisons between liarozole and placebo groups (intent-to-treat population).
Table S2. Liarozole predose and near-peak plasma concentrations.
Table S3. Summary of adverse events (safety population).
Fig. S1. Change in mean Dermatology Life Quality Index (DLQI) over time (intent-to-treat population; last observation carried forward).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.